Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CMS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment. |
| Treatment Sequence 2 | EXPERIMENTAL | Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment. |
| Name | Type | Description |
|---|---|---|
| CMS | DRUG | Multiple doses of CMS over 2.5 days |
| RO7033877 | DRUG | Multiple doses of RO7033877 over 2.5 days |
| RO7033877 + CMS | DRUG | Multiple doses of RO7033877 and CMS over 2.5 days |
Inclusion Criteria: * Adult male or female (of non childbearing potential) healthy volunteers between 18 to 55 years * Body mass index (BMI) between 18 and 30 kg/m2 * Non smokers * Use adequate contraception methods Exclusion Criteria: * Evidence of active of chronic disease * Regular consumption...
CMS, or colistin methanesulfonate sodium, is an investigational small molecule being studied in a Phase 1 clinical trial in healthy volunteers. The trial, NCT02156323, was completed in the Netherlands and enrolled 28 participants. CMS is being developed by Roche Holding AG (RHHBY).
CMS is being studied for use in healthy volunteers as part of a drug-drug interaction trial. The Phase 1 study investigated the interaction between multiple doses of RO7033877 and multiple doses of CMS. The trial has been completed, and CMS remains in clinical development.
CMS is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored the Phase 1 clinical trial NCT02156323, which investigated CMS in healthy volunteers. The study has been completed.
CMS is in Phase 1 clinical development. The completed trial, NCT02156323, was a Phase 1 study in healthy volunteers that enrolled 28 participants. CMS is investigational and not yet approved for any use.
CMS has one clinical trial, NCT02156323, a Phase 1 study in healthy volunteers. The trial, completed in the Netherlands, investigated the drug-drug interaction between multiple doses of RO7033877 and CMS. It enrolled 28 participants and was a controlled, randomized study.
Yes, CMS is the abbreviation for colistin methanesulfonate sodium. The Phase 1 trial NCT02156323 studied the interaction between RO7033877 and colistin methanesulfonate sodium (CMS) in healthy volunteers. The trial has been completed.